mTOR inhibition for cancer therapy : past, present and future / edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
"This book describes the challenges involved in developing m TOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel direction...
Saved in:
| Other Authors: | , , |
|---|---|
| Format: | Ebook |
| Language: | English |
| Published: |
Paris :
Springer,
2016.
|
| Subjects: | |
| Online Access: | Springer eBooks |
| Summary: | "This book describes the challenges involved in developing m TOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of m TOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from m TOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation."--Publisher's website. |
|---|---|
| Physical Description: | 1 online resource (vi, 300 pages) : illustrations (some colour) |
| Format: | Mode of access: World Wide Web. |
| Bibliography: | Includes bibliographical references. |
| ISBN: | 2817804929 9782817804927 |